Histogenics Corp. (NASDAQ:HSGX) major shareholder Split Rock Partners Ii, Lp purchased 276,801 shares of the firm’s stock in a transaction that occurred on Thursday, September 29th. The stock was bought at an average price of $2.25 per share, with a total value of $622,802.25. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Shares of Histogenics Corp. (NASDAQ:HSGX) traded down 3.43% during midday trading on Monday, reaching $3.10. The company had a trading volume of 80,397 shares. The firm’s market cap is $41.14 million. Histogenics Corp. has a 52-week low of $1.39 and a 52-week high of $4.97. The company’s 50-day moving average is $3.18 and its 200-day moving average is $2.33.

Histogenics Corp. (NASDAQ:HSGX) last issued its quarterly earnings data on Thursday, August 11th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.60) by $0.01. During the same quarter in the previous year, the company posted ($0.58) earnings per share. Equities research analysts expect that Histogenics Corp. will post ($2.11) EPS for the current fiscal year.

A number of equities analysts recently weighed in on HSGX shares. BTIG Research upgraded Histogenics Corp. from a “neutral” rating to a “buy” rating and set a $3.50 price target for the company in a research report on Thursday, August 11th. Zacks Investment Research upgraded Histogenics Corp. from a “hold” rating to a “buy” rating and set a $3.25 price target for the company in a research report on Friday, August 26th. William Blair lowered Histogenics Corp. from an “outperform” rating to a “market perform” rating in a research report on Wednesday, September 7th. Finally, Needham & Company LLC increased their price target on Histogenics Corp. from $8.00 to $11.00 and gave the company a “buy” rating in a research report on Monday, September 19th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $7.65.

A hedge fund recently raised its stake in Histogenics Corp. stock. Sabby Management LLC boosted its position in Histogenics Corp. (NASDAQ:HSGX) by 28.0% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 150,630 shares of the company’s stock after buying an additional 32,965 shares during the period. Sabby Management LLC owned about 1.14% of Histogenics Corp. worth $345,000 as of its most recent SEC filing. 38.63% of the stock is currently owned by institutional investors and hedge funds.

About Histogenics Corp.

Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company’s product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.

5 Day Chart for NASDAQ:HSGX

Receive News & Stock Ratings for Histogenics Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics Corp. and related stocks with our FREE daily email newsletter.